New combo therapy offers hope for head and neck cancer patients who Can't take chemo
NCT ID NCT07333274
First seen Jan 12, 2026 · Last updated Apr 28, 2026 · Updated 18 times
Summary
This study tests whether adding the targeted drug nimotuzumab to standard radiation therapy helps people with advanced head and neck cancer live longer without the cancer growing or spreading. It is for patients who cannot receive platinum-based chemotherapy. About 335 adults will be randomly assigned to get radiation alone or radiation plus nimotuzumab. The main goal is to see if the combination improves the chance of staying cancer-free for two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD & NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong First Medical University Affiliated Cancer Hospital
RECRUITINGShandong, Province, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.